Finzati - Logo
NAGE logo

Niagen Bioscience Inc

NAGE • Biotechnology
$3.17
▲ +0.06 (+1.93%)
Current price
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$268.07M
Growth
—
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 13.4%Positive revenue growth · 13.0%Positive free cash flow · 0.17Manageable debt level · 0.04Healthy liquidity · 4.86
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:14 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$3.17
Change1.93%
Shares Out84.57M
Market Cap$268.07M
Enterprise Value$202.56M
52W Range2.87 - 11.29
Beta2.08
P/E14.38
P/S2.06
P/B3.26
P/FCF66.17
EV/Sales1.55

Investment DNA

How strong this company looks for long-term investors

67
out of 100
Business Quality
Margins, moat, returns
70/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
42/100
Why this score▼
Stable or improving margins · 13.4%Positive revenue growth · 13.0%Positive free cash flow · 0.17Manageable debt level · 0.04Healthy liquidity · 4.86

Analyst view

Analyst sentiment and price target

NAGE
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
100/100
Bullish
Bullish
5
Hold
0
Bearish
0
Price Target
2026-08-06
Low
$10.00
Mean
$10.33
Median
$10.00
High
$11.00

Company Overview

IPO: 6/24/2015
Industry: Biotechnology
P/B i: 3.26
Debt / Equity i: 0.04
Operating Margin: 11.05%
Net Margin: 13.43%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.04
Current Ratio: 4.86
Quick Ratio: 3.83
Status: Good

Insider Transactions

Recent executive and insider activity

Fried Robert N
Transaction: 06/30/2026
BUY
Change
+1,106
Price
$2.71
Filing
07/08/2026
Type
BUY
Pamir Ozan
Transaction: 06/30/2026
BUY
Change
+4,255
Price
$2.71
Filing
07/08/2026
Type
BUY
Lopez Carlos Luis
Transaction: 06/30/2026
BUY
Change
+2,314
Price
$2.71
Filing
07/08/2026
Type
BUY